Skip to content
Research/Peptides/CJC-1295 No DAC (Modified GRF 1-29)

CJC-1295 No DAC (Modified GRF 1-29)

Mod GRF 1-29, CJC No DAC. Short-acting GHRH analog without DAC modification. Creates a high, pulsatile GH release, more natural GH stimulation. Combined with Ipamorelin for synergistic effects.

Intelligence Profile

Science

Mechanism of Action

Limited evidence available. No peer-reviewed studies or clinical trials were retrieved for CJC-1295 No DAC (Modified GRF 1-29) to establish its mechanism of action.

Based on its structural designation as "Modified GRF 1-29," this compound appears to be a synthetic analog of growth hormone-releasing factor (GRF), also known as growth hormone-releasing hormone (GHRH). The "1-29" indicates it contains the first 29 amino acids of the native GHRH sequence.

Theoretically, as a GHRH analog, CJC-1295 No DAC would be expected to:

  • Bind to GHRH receptors on pituitary somatotrophs
  • Stimulate cyclic adenosine monophosphate (cAMP) signaling pathways
  • Promote growth hormone release from the anterior pituitary

However, without published research specifically examining CJC-1295 No DAC, its actual molecular mechanisms, receptor binding affinity, pharmacokinetics, and physiological effects remain unestablished in the scientific literature.

The "No DAC" designation suggests it lacks a drug affinity complex that would extend its half-life, potentially resulting in shorter duration of action compared to other modified GHRH analogs.

Disclaimer: This theoretical framework is based on structural similarities to known compounds. Actual mechanisms require experimental validation through peer-reviewed research.